Prospects for the development of fusion inhibitors to treat human respiratory syncytial virus infection

Current Opinion in Drug Discovery and Development

Volumn 12, Issue 4, 2009, Pages 479-487

  Bonfanti, Jean François ^a   Roymans, Dirk ^b  

^a Campus de Maigremont   (France)

^b Virco BVBA   (Belgium)

Author keywords

Antibodies; Antiviral drugs; Fusion inhibitor; Human respiratory syncytial virus; Viral fusion

Indexed keywords

1 CYCLOPROPYL 1,3 DIHYDRO 3 [[1 (4 HYDROXYBUTYL) 1H BENZIMIDAZOL 2 YL]METHYL] 2H IMIDAZO[4,5 C]PYRIDIN 2 ONE; ALN RSV 01; BTA 9881; CL 387626; HYBRID PROTEIN; IMIDAZOISOINDOLONE DERIVATIVE; MOTAVIZUMAB; PALIVIZUMAB; RFI 641; RIBAVIRIN; RSV 604; TMC 353121; UNCLASSIFIED DRUG; VIRUS FUSION PROTEIN; VP 14637;

HIGH RISK PATIENT; HUMAN; INFANT DISEASE; NONHUMAN; POPULATION RISK; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; SINGLE DRUG DOSE; VIRUS CELL INTERACTION; VIRUS INFECTION;

ANTIBODIES, MONOCLONAL; ANTIVIRAL AGENTS; BENZIMIDAZOLES; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; HUMANS; MOLECULAR STRUCTURE; PROTEIN FOLDING; PYRIDINES; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; SMALL MOLECULE LIBRARIES; VIRAL FUSION PROTEINS;

EID: 67649998628     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (71)

1. Chanock R, Roizman B, Myers R: Recovery from infants with respiratory illness of a virus related to chimpanzee coryza agent (CCA). I. Isolation, properties and characterization.Am J Hyg (1957) 66(3):281-290.
2. Chanock R, Finberg L: Recovery from infants with respiratory illness of a virus related to chimpanzee coryza agent (CCA). II. Epidemiologic aspects of infection in infants and young children. Am J Hyg (1957) 66(3):291-300.
3. Ottolini MG, Hemming VG: Prevention and treatment recommendations for respiratory syncytial virus infection. Background and clinical experience 40 years after discovery.Drugs (1997) 54(6):867-884.
4. Simoes EAF: Respiratory syncytial virus infection: Pathogenesis, treatment and prevention. Curr Opin Infect Dis(1997) 10(3):213-220.
5. Simoes EAF: Respiratory syncytial virus infection. Lancet (1999) 354(9181):847-852.
6. Hall CB, Weinberg GA, Iwane MK, Blumkin AK, Edwards KM, Staat MA, Auinger P, Griffin MR, Poehling KA, Erdman D, Grijalva CG et al: The burden of respiratory syncytial virus infection in young children. N Engl J Med (2009) 360(6):588-598. ·· Reports the results from a 5-year prospective, population-based surveillance of acute respiratory infections in children under the age of 5 years, demonstrating that 18% of the enrolled patients were diagnosed with hRSV and that 20% of hospitalizations due to acute respiratory infections were associated with hRSV.
7. Walsh EE, Peterson DR, Falsey AR: Risk factors for severe respiratory syncytial virus infection in elderly persons.J Infect Dis (2004) 189(2):233-238.
8. Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE: Respiratory syncytial virus infection in elderly and high-risk adults. New Engl J Med (2005) 352(17):1749-1759. · Provides an epidemiological analysis of hRSV incidence in community-dwelling elderly persons and at-risk adults, and establishes the importance of hRSV disease in these patient groups.
9. Shay DK, Holman RC, Newman RD, Liu LL, Stout JW, Anderson LJ: Bronchiolitis-associated hospitalizations among US children, 1980 - 1996. J Am Med Assoc (1999) 282(15):1440-1446.
10. Leader S, Kohlhase K: Respiratory syncytial virus-coded pediatric hospitalizations, 1997 to 1999. Pediatr Infect Dis J (2002) 21(7):629-632.
11. Mejías A, Chávez-Bueno S, Ríos AM, Fonseca-Aten M, Gómez AM, Jafri HS, Ramilo O: Asthma and respiratory syncytial virus. New opportunities for therapeutic intervention. Ann Pediat(2004) 61(3):252-260.
12. Sigurs N, Gustafsson PM, Bjarnason R, Lundberg F, Schmidt S, Sigurbergsson F, Kjellman B: Severe respiratory syncytial virus bronchiolitis in infancy and asthma and allergy at age 13.Am J Respir Cri Care Med (2005) 171(2):137-141. · Describes a prospective study in 47 children who were hospitalized with hRSV bronchiolitis in infancy and followed up until 13 years of age, and who exhibited a significantly higher incidence of asthma, recurrent wheezing and allergic rhinoconjunctivitis compared with control subjects.
13. Hansbro NG, Horvat JC, Wark PA, Hansbro PM: Understanding the mechanisms of viral induced asthma: New therapeutic directions. Pharmacol Ther (2008) 117(3):313-353.
14. Weisman LE: Populations at risk for developing respiratory syncytial virus and risk factors for respiratory syncytial virus severity: Infants with predisposing conditions. Pediatr Infect Dis J (2003) 22(2 Suppl):S33-S37.
15. Hall CB, Powell KR, MacDonald NE, Gala CL, Menegus ME, Suffin SC, Cohen HJ: Respiratory syncytial virus infection in children with immunocompromised immune function. New Engl J Med (1986) 315(2):77-81. · Describes a prospective study in 608 immunocompromised children who exhibited more severe disease and mortality caused by hRSV than was observed in immunocompetent children.
16. Feltes TF, Sondheimer HM: Palivizumab and the prevention of respiratory syncytial virus illness in pediatric patients with congenital heart disease. Expert Opin Biol Ther (2007) 7(9):1471- 1480.
17. Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, Anderson LJ, Fukuda K: Mortality associated with influenza and respiratory syncytial virus in the United States.J Am Med Assoc (2003) 289(2):179-186.
18. Falsey AR, Walsh EE: Respiratory syncytial virus infection in adults. Clin Microbiol Rev (2000) 13(3):371-384.
19. Schmidt AC: Progress in respiratory virus vaccine development.Semin Respir Crit Care Med (2007) 28(2):243-252.
20. van Drunen Littel-van den Hurk S, Mapletoft JW, Arsic N, Kovacs-Nolan J: Immunopathology of hRSV infection: Prospects for developing vaccines without this complication.Rev Med Virol (2007) 17(1):5-34.
21. Piedra PA: Clinical experience with respiratory syncytial virus vaccines. Pediatr Infect Dis J (2003) 22(2 Suppl):S94-S99.
22. Castilow EM, Olson MR, Varga SM: Understanding respiratory syncytial virus (hRSV) vaccine-enhanced disease. Immunol Res(2007) 39(1-3):225-239.
23. Moghaddam A, Olszewska W, Wang B, Tregoning JS, Helson R, Sattentau QJ, Openshaw PJ: A potential molecular mechanism for hypersensitivity caused by formalin-inactivated vaccines.Nat Med (2006) 12(8):905-907. ·· Elegant study demonstrating Th2 helper cell-boosting by carbonyl groups on formaldehyde-treated vaccine antigens, leading to the enhancement of hRSV disease.
24. Nikitenko AA, Raifeld YE, Wang TZ: The discovery of RFI-641 as a potent and selective inhibitor of the respiratory syncytial virus. Bioorg Med Chem Lett (2001) 11(8):1041-1044.
25. Andries K, Moeremans M, Gevers T, Willebrords R, Sommen C, Lacrampe J, Janssens F, Wyde PR: Substituted benzimidazoles with nanomolar activity against respiratory syncytial virus.Antiviral Res (2003) 60(3):209-219. ·· Describes the JNJ-2408068 chemical series, which was important for the discovery of TMC-353121.
26. Douglas JL, Panis ML, Ho E, Lin KY, Krawczyk SH, Grant DM, Cai R, Swaminathan S, Cihlar T: Inhibition of respiratory syncytial virus fusion by the small molecule VP-14637 via specific interactions with F protein. J Virol (2003) 77(9):5054-5064.
27. Cianci C, Yu KL, Combrink K, Sin N, Pearce B, Wang A, Civiello R, Voss S, Luo G, Kadow K, Genovesi EV et al: Orally active fusion inhibitor of respiratory syncytial virus. Antimicrob Agents Chemother (2004) 48(2):413-422. · Describes the in vitro and in vivo activities of the BMS-433771 series.
28. Bonfanti JF, Meyer C, Doublet F, Fortin J, Muller P, Queguiner L, Gevers T, Janssens P, Szel H, Willebrords R, Timmerman P et al: Selection of a respiratory syncytial virus fusion inhibitor clinical candidate. 2. Discovery of a morpholinopropylaminobenzimidazole derivative (TMC353121). J Med Chem(2008) 51(4):875-896. ·· Describes the discovery of TMC-353121.
29. Kielian M, Rey FA: Virus membrane-fusion proteins: More than one way to make a hairpin. Nat Rev Microbiol (2006) 4(1):67-76.
30. Colman PM, Lawrence MC: The structural biology of type I viral membrane fusion. Nat Rev Mol Cell Biol (2003) 4(4):309-319.
31. Yin H-S, Wen X, Paterson RG, Lamb RA, Jardetzky TS: Structure of the parainfluenza virus 5 F protein in its metastable, prefusion conformation. Nature (2006) 439(7072):38-44. ·· Landmark paper that dramatically increased mechanistic insights into paramyxovirus fusion.
32. Chan DC, Kim PS: HIV entry and its inhibition. Cell (1998) 93(5):681-684.
33. Cianci C, Langley DR, Dischino DD, Sun Y, Yu KL, Stanley A, Roach J, Li Z, Dalterio R, Colonno R, Meanwell NA et al: Targeting a binding pocket within the trimer-of-hairpins: Small-molecule inhibition of viral fusion. Proc Natl Acad Sci USA (2004) 101(42):15046-15051. · Provides the first evidence that small molecules may target a hydrophobic pocket in the hRSV 6HB. In addition, presented data suggests the occurrence of potential synergistic effects of small molecules that inhibit hRSV fusion.
34. Douglas JL, Panis ML, Ho E, Lin KY, Krawczyk SH, Grant DM, Cai R, Swaminathan S, Chen X, Cihlar T: Small molecules VP-14637 and JNJ-2408068 inhibit respiratory syncytial virus fusion by similar mechanisms. Antimicrob Agents Chemother (2005) 49(6):2460-2466.
35. Morton CJ, Cameron R, Lawrence LJ, Lin B, Lowe M, Luttick A, Mason A, McKimm-Breschkin J, Parker MW, Ryan J, Smout M et al: Structural characterization of respiratory syncytial virus fusion inhibitor escape mutants: Homology model of the F protein and a syncytium formation assay. Virology (2003) 311(2):275-288.
36. Johnson S, Oliver C, Prince GA, Hemming VG, Pfarr DS, Wang SC, Dormitzer M, O'Grady J, Koenig S, Tamura JK, Woods R et al: Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis (1997) 176(5):1215-1224. ·· Describes the molecular engineering of palivizumab, the only currently approved mAb on the market for passive immunoprophylaxis in hRSV.
37. Bonfanti JF, Doublet F, Fortin J, Lacrampe J, Guillemont J, Muller P, Queguiner L, Arnoult E, Gevers T, Janssens P, Szel H et al: Selection of a respiratory syncytial virus fusion inhibitor clinical candidate, part 1: Improving the pharmacokinetic profile using the structure-property relationship. J Med Chem (2007) 50(19):4572-4584. ·· Describes the modifications applied to the JNJ-2408068 scaffold in order to improve the PK properties in terms of tissue retention.
38. Zhao X, Singh M, Malashkevich VN, Kim PS: Structural characterization of the human respiratory syncytial virus fusion protein core. Proc Natl Acad Sci USA (2000) 97(26): 14172-14177. ·· Describes the X-ray structure of the hRSV 6HB which has been instrumental in the design of new small-molecule fusion inhibitors against hRSV, and in the elucidation of the mechanism of action of these inhibitors.
39. Chan DC, Chutkowski CT, Kim PS: Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target. Proc Natl Acad Sci USA (1998) 95(26):15613-15617. · Suggests for the first time that the hydrophobic pocket in the HR1 trimeric coiled-coil is a druggable target.
40. Bond S, Draffan A, Lambert J, Lim C-Y, Lin B, Luttick A, Mitchell J, Morton C, Nearn R, Sanford V, Tucker S: Discovery of a new class of polycyclic RSV inhibitors. Antiviral Res (2007) 74(3):A30.
41. MedImmune: MedImmune, Gaithersburg, MD, USA (2009). www.medimmune.com
42. Biota: Biota Holdings Ltd, Melbourne, VIC, Australia (2009). www. biota.com.au
43. Yu KL, Zhang Y, Civiello RL, Kadow KF, Cianci C, Krystal M, Meanwell NA: Fundamental structure-activity relationships associated with a new structure class of respiratory syncyitial virus inhibitor. Bioorg Med Chem Lett (2003) 13(13):2141-2144.
44. Yu KL, Zhang Y, Civiello RL, Trehan AK, Pearce BC, Yin Z, Combrink KD, Gulgeze HB, Wang XA, Kadow KF, Cianci CW et al: Respiratory syncytial virus inhibitors. Part 2: Benzimidazol-2-one derivatives. Bioorg Med Chem Lett (2004) 14(5):1133-1137.
45. Yu KL, Wang XA, Civiello RL, Trehan AK, Pearce BC, Yin Z, Combrink KD, Gulgeze HB, Zhang Y, Kadow KF, Cianci CW et al: Respiratory syncytial virus inhibitors. Part 3: Water-soluble benzimidazol-2-one derivatives with antiviral activity in vivo. Bioorg Med Chem Lett (2006) 16(5):1115-1122.
46. Yu KL, Sin N, Civiello RL, Wang XA, Combrink KD, Gulgeze HB, Venables BL, Wright JJ, Dalterio RA, Zadjura L, Marino A et al: Respiratory syncytial virus inhibitors. Part 4: Optimisation for oral bioavailability. Bioorg Med Chem Lett (2007) 17(4):895-901.
47. Wang XA, Cianci CW, Yu KL, Combrink KD, Thuring JW, Zhang Y, Civiello RL, Kadow KF, Roach J, Li Z, Langley DR et al: Respiratory syncytial virus inhibitors. Part 5: Optimisation of benzimidazole substitution patterns towards derivatives with improved activity. Bioorg Med Chem Lett (2007) 17(16): 4592-4598.
48. Combrink KD, Gulgeze HB, Thuring JW, Yu KL, Civiello RL, Zhang Y, Pearce BC, Yin Z, Langley DR, Kadow KF, Cianci CW et al: Respiratory syncytial virus inhibitors. Part 6: An examination of the effect of structural variation of the benzimidazol-2- one heterocycle moiety. Bioorg Med Chem Lett (2007) 17(17): 4784-4790.
49. Meanwell NA, Krystal M: Respiratory syncytial virus - The discovery and optimisation of orally bioavailable fusion inhibitors. Drugs Future (2007) 32(5):441-455.
50. Cianci C, Genovesi EV, Lamb L, Medina I, Yang Z, Zadjura L, Yang H, D'Arienzo C, Sin N, Yu KL, Combrink K et al: Oral efficacy of a respiratory syncytial virus inhibitor in rodent models of infection. Antimicrob Agents Chemother (2004) 48(7):2448-2454.
51. Cianci C, Meanwell N, Krystal M: Antiviral activity and molecular mechanism of an orally active respiratory syncytial virus fusion inhibitor. J Antimicrob Chemother (2005) 55(3):289-292.
52. Ding WD, Mitsner B, Krishnamurthy G, Aulabaugh A, Hess CD, Zaccardi J, Cutler M, Feld B, Gazumyan A, Raifeld Y, Nikitenko A et al: Novel and specific respiratory syncytial virus inhibitors tat target virus fusion. J Med Chem (1998) 41(15):2671-2675.
53. Nikitenko AA, Raifeld YE, Wang TZ: The discovery of RFI-641 as a potent and selective inhibitor of the respiratory syncytial virus. Bioorg Med Chem Lett (2001) 11(8):1041-1044.
54. Huntley CC, Weiss WJ, Gazumanyan J, Buklan A, Feld B, Hu W, Jones TR, Murphy T, Nikitenko AA, O'Hara B, Prince G et al: RFI-641, a potent respiratory syncytial virus inhibitor. Antimicrob Agents Chemother (2002) 46(3):841-847.
55. Nikitenko AA, Raifeld YE, Mitsner B, Newman H: Pyrimidine containing hRSV fusion inhibitors. Bioorg Med Chem Lett (2005) 15(2):427-430.
56. Razinkov V, Gazumyan A, Nikitenko A, Ellestad G, Krishnamurthy G: RFI-641 inhibits entry of respiratory syncytial virus via interactions with fusion protein. Chem Biol (2001) 8(7):645-659.
57. Wyde PR, Laquerre S, Chetty S, Gilbert BE, Nitz T, Pevear DC: Antiviral efficacy of VP14637 against respiratory syncytial virus in vitro and in Cotton rats following delivery by small droplet aerosol. Antiviral Res (2005) 68(1):18-26.
58. Viropharma Incorporated: Viropharma Inc, Exton, PA, USA (2009). www.viropharma.com59. Lamprecht CL, Krause HE, Mufson MA: Role of maternal antibody in pneumonia and bronchiolitis due to respiratory syncytial virus. J Infect Dis (1976) 134(3):211-217.
59. Henderson FW, Collier AM, Clyde WA Jr, Denny FW: Respiratorysyncytial- virus infections, reinfections and immunity. A prospective, longitudinal study in young children. N Engl J Med(1979) 300(10):530-534.
60. Fernald GW, Almond JR, Henderson FW: Cellular and humoral immunity in recurrent respiratory syncytial virus infections.Pediatr Res (1983) 17(9):753-758.
61. Kasel JA, Walsh EE, Frank AL, Baxter BD, Taber LH, Glezen WP: Relation of serum antibody to glycoproteins of respiratory syncytial virus with immunity to infection in children.Viral Immunol (1988) 1(3):199-205.
62. Nokes JD, Cane PA: New strategies for control of respiratory syncytial virus infection. Curr Opin Infect Dis (2008) 21(6):639- 643.
63. Del Vecchio AM, Sarisky RT: Cold virus fusion or stopping fusion cold - Inhibitors of the human respiratory syncytial virus F protein. Recent Pat Antiinfect Drug Discov (2006) 1(2):247-254.
64. Wu H, Pfarr DS, Losonsky GA, Kiener PA: Immunoprophylaxis of RSV infection: Advancing from RSV-IGIV to palivizumab and motavizumab. Curr Top Microbiol Immunol (2008) 317:103-123.
65. Wu H, Pfarr DS, Johnson S, Brewah YA, Woods RM, Patel NK, White WI, Young JF, Kiener PA: Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract. J Mol Biol (2007) 368(3):652-665. ·· Describes the molecular engineering of motavizumab, a next-generation mAb for passive immunization.
66. Boukhvalova MS, Prince GA, Blanco JC: Respiratory syncytial virus infects and abortively replicates in the lungs in spite of preexisting immunity. J Virol (2007) 81(17):9443-9450. · Describes for the first time an abortive replication of hRSV in Cotton rats, and also provides an explanation of the mechanism of action of palivizumab.
67. MedImmune: Phase 3 Data Regarding Anti-RSV Antibody To Be Presented at Pediatric Academic Societies (PAS) Annual Meeting. Press Release (2008): April 05.
68. Chapman J, Abbott E, Alber DG, Baxter RC, Bithell SK, Henderson EA, Carter MC, Chambers P, Chubb A, Cockerill GS, Collins PL et al: RSV604, a novel inhibitor of respiratory syncytial virus replication. Antimicrob Agents Chemother (2007) 51(9):3346-3353.
69. DeVincenzo J, Cehelsky JE, Alvarez R, Elbashir S, Harborth J, Toudjarska I, Nechev L, Murugaiah V, Van Vliet A, Vaishnaw AK, Meyers R: Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV). Antiviral Res (2008) 77(3):225-231. · Presents phase I clinical trial data on the use of a siRNA against hRSV infection, potentially representing a new therapeutic avenue for treatment.
70. Moscona A: Oseltamivir resistance - Disabling our influenza defenses. N Engl J Med (2005) 353(25):2633-2636.
71. Biota Scientific Management Pty Ltd (Bond S, Sanford VA, Lambert JN, Lim CY, Mitchell JP, Draftan AG, Nearn RH): Polycyclic agents for the treatment of respiratory syncytial virus infections.WO-2005061513 (2005). ·· Describes the discovery of imidazoisoindolone derivatives as inhibitors of hRSV.